VERTEX PHARMACEUTICALS INC / MA
Congressional Trades
Whale Activity
- Increased759
- New149
- Held259
- Decreased557
- Closed101
- No prior filing76
| Filer | Shares | Value | Change |
|---|---|---|---|
| Capital World Investors | 26.0M | $13.58B | decreased |
| BlackRock, Inc. | 23.8M | $12.44B | decreased |
| Capital Research Global Investors | 17.8M | $9.31B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.6M | $8.68B | increased |
| STATE STREET CORP | 12.0M | $6.29B | increased |
| Invesco Ltd. | 8.3M | $4.33B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 6.1M | $3.17B | increased |
| JPMORGAN CHASE & CO | 5.7M | $3.00B | decreased |
| Capital International Investors | 5.1M | $2.65B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9M | $2.59B | increased |
| FRANKLIN TEMPLETON INC | 4.5M | $2.45B | increased |
| LOOMIS SAYLES & CO L P | 3.6M | $1.89B | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Thornberry NancyDirector · Director | Sale | −1,000 | $547.86 | $548K | Nov 16, 2026 | Form 4 ↗ |
| Bhatia Sangeeta N.Director · Director | Sale | −271 | $547.86 | $148K | Nov 16, 2026 | Form 4 ↗ |
| WAGNER CHARLES F JREVP, CO & FO | Sale | −15.3K | $547.87 | $8.4M | Nov 12, 2026 | Form 4 ↗ |
| Kewalramani ReshmaCEO & President · Director | Sale | −11.9K | $531.53 | $6.3M | Nov 6, 2026 | Form 4 ↗ |
| van Grunsven JasperEVP, CP and NPPO | Grant / award | +8,682 | $0.00 | $0 | Sep 8, 2026 | Form 4 ↗ |
| Ambrose KristenSVP & Chief Accounting Officer | Grant / award | +5,000 | $0.00 | $0 | Aug 28, 2026 | Form 4 ↗ |
| SACHS BRUCE IDirector | Gift | −6,000 | $0.00 | $0 | Aug 27, 2026 | Form 4 ↗ |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant / award | +8,251 | $0.00 | $0 | Jul 21, 2026 | Form 4 ↗ |
| Sachdev AmitEVP Chief Patient & Ext Af Off | Grant / award | +8,251 | $0.00 | $0 | Jul 21, 2026 | Form 4 ↗ |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Sale | −1,500 | $524.99 | $787K | Jul 2, 2026 | Form 4 ↗ |
| McKechnie DuncanEVP, Chief Commercial Officer | Sale | −1,541 | $519.00 | $800K | Jul 2, 2026 | Form 4 ↗ |
| Liu JoyEVP and Chief Legal Officer | Sale | −828 | $502.71 | $416K | Jul 1, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −596 | $482.50 | $288K | Jun 26, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,020 | $462.17 | $471K | Jun 18, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −4,062 | $450.00 | $1.8M | Jun 15, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,745 | $450.00 | $785K | Jun 5, 2026 | Form 4 ↗ |
| Liu JoyEVP and Chief Legal Officer | Sale | −828 | $439.91 | $364K | Jun 1, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,974 | $450.00 | $888K | May 29, 2026 | Form 4 ↗ |
| Bunnage Mark E.EVP, Chief Scientific Officer | Sale | −33 | $453.45 | $15K | May 15, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,354 | $453.45 | $614K | May 15, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Growth Fund of America | 12.9M | $7.03B | 1.99% | Aug 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 8.1M | $4.00B | 0.17% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 6.6M | $3.27B | 0.20% | Jun 30, 2026 |
| Investment Co of America | 6.3M | $3.11B | 1.69% | Jun 30, 2026 |
| American Balanced Fund | 5.6M | $2.76B | 0.96% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 5.4M | $2.68B | 0.55% | Jun 30, 2026 |
| AMCAP Fund | 4.7M | $2.58B | 2.73% | Aug 31, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 3.3M | $1.79B | 0.21% | Aug 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 3.5M | $1.73B | 0.20% | Jun 30, 2026 |
| New Perspective Fund | 3.4M | $1.67B | 0.98% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list VRTX's shares (CUSIP 92532F100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Corporate Lobbying
- CGCN GROUP, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · HCR, MMM$50K
Filing ↗ - MARSHALL & POPP, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · MMM, TRD$60K
Filing ↗ - MCLARTY INBOUND LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · TRD$90K
Filing ↗ - AVENUE SOLUTIONSVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · MMM, HCR$60K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · BUD, HCR, MMM$80K
Filing ↗
Government Contracts
No federal contract awards found for VERTEX PHARMACEUTICALS INC / MA.
U.S. Patents
No USPTO patent applications found for VERTEX PHARMACEUTICALS INC / MA.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Operating income | $4.17B | -$232.9M | $3.83B | $4.31B | $2.78B |
| Net income | $3.95B | -$535.6M | $3.62B | $3.32B | $2.34B |
| Diluted EPS | $15.32 | -$2.08 | $13.89 | $12.82 | $9.01 |
| Operating cash flow | $3.63B | -$492.6M | $3.54B | $4.13B | $2.64B |
| Cash and equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.79B |
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B |
| Shareholders' equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B |
As VERTEX PHARMACEUTICALS INC / MA tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 13, 2026 ↗
Stock Splits
- 2-for-1Stock splitAug 24, 2000
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeOct 20, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 8.01, 9.01Material agreement · Reg FD disclosure · Other eventsJul 7, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteMay 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 4, 2026
EDGAR ↗






